The field of obesity management is quickly evolving. New drug therapies and bariatric surgery are effective, but a larger understanding of social determinants, genetics, and the psychology behind obesity are proving to be essential pieces of the puzzle. Dismantling the myth that obesity is a lack of willpower or a “calories in, calories out” conundrum is necessary to shift the conversation away from placing blame and toward effective management.
Cardiometabolic Health Congress (CMHC) sat down with Dr. Keith C. Ferdinand, the Gerald S. Berenson Endowed Chair in preventive cardiology at Tulane School of Medicine
Experts in both obesity medicine and dermatology have a lot to say about Ozempic, the latest glucose-control drug being used for weight loss. According to
The roots of cardiometabolic disease begin in childhood, but many clinicians do not feel confident about screening, diagnosing, and treating these conditions early on. This
Obstetricians call pregnancy a “stress test” for a woman’s body. The increased blood volume puts extra burden on a woman’s circulatory and cardiovascular systems, and
A combination GIP and GLP-1 receptor could be the next groundbreaking treatment option for people with overweight or obesity, researchers reported. The first-of-its-kind class of
The following blog has been republished with permission from our partners at Healio. You can read the original article here. Compared with conventional treatment, bariatric
Obesity
Cardiometabolic Disease
Cardiometabolic Disease
Watch Drs. Eckel and Harrison discuss some additional perspectives on the screening, diagnosis and emerging treatment options for NASH. Recorded Dec.1, 2022.
Watch CMHC faculty Dr. Barb discussing some practical pearls and the current treatment approaches for NASH. Recorded Dec.15, 2022.
CMHC Chair Robert Eckel and faculty Holly Wyatt, MD and Michelle Look, MD recap the obesity session topics discussed at the 16th Annual CMHC, including the importance of assessing and addressing pre-obesity, patient motivation advice, and considerations for long-term weight maintenance and obesity management.
CMHC Chair Robert Eckel, MD, recaps the session on rare obesity disorders discussed at the 16th Annual CMHC with session presenters Joan Han, MD, and Clair Francomano, MD. The session discussed monogenic disorders of obesity, including leptin pathway defects and Alström syndrome, as well as practical pearls for screening, diagnosis, and treatment.
NAFLD = non-alcoholic fatty liver disease; NASH = non-alcoholic steatohepatitis
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Cardiometabolic Health Congress
1801 N Military Trail, Ste 110
Boca Raton, FL, 33431
Copyright © 2023, Cardiometabolic Health Congress. All Rights Reserved.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
